NEW YORK, NY - August 25, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than September 28, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. The complaint alleges that on July 27, 2026, before the market o…

Capricor Therapeutics Inc. stocks have been trading up by 14.26 percent following highly positive news driving investor optimism Key Takeaways Traders Need To Know Shares of CAPR ripped roughly 80–100% in premarket trading after Q2 results and a positive FDA update on deramiocel, showing powerful event‑driven momentum. Cantor Fitzgerald upgraded Capricor Therapeutics to Overweight from…

Capricor Therapeutics Inc. stocks have been trading up by 14.26 percent amid optimism over promising clinical trial progress. Key Takeaways Wall Street’s tone has flipped as Cantor Fitzgerald boosted its rating on CAPR to Overweight and hiked its price target to $28 from $3.50 after Q2 earnings.

Capricor Therapeutics (CAPR) stock gains as Oppenheimer upgrades the company after the FDA extended review period for its lead drug deramiocel. Read more here.

/PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc....